MAR 20, 2018 09:00 AM PDT

Heart failure: A Global Challenge From Prognosis to Management

C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Vice Chief of Medicine, Baylor University Medical Center , and Principal Faculty in internal medicine, Texas A & M University Health Sciences Center
      After receiving a bachelor's degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School in Dallas. He went on to complete his internal medicine residency at the University of Washington in Seattle, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master's degree in public health at the University of Michigan. Dr. McCullough is Vice Chief of Medicine at Baylor University Medical Center in Dallas, TX and is a Principal Faculty in internal medicine for the Texas A & M University Health Sciences Center. He is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state with over 1000 publications including the "Interface between Renal Disease and Cardiovascular Illness" in Braunwald's Heart Disease Textbook. Dr. McCullough is a recipient of the Simon Dack Award from the American College of Cardiology and the International Vicenza Award in Critical Care Nephrology for his scholarship and research. Dr. McCullough is a founder and current president of the Cardiorenal Society of America, an organization dedicated to bringing cardiologists and nephrologists together to work on the emerging problem of cardiorenal syndromes. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, and other top-tier journals worldwide. He is the co-editor of Reviews in Cardiovascular Medicine, associated editor of the American Journal of Cardiology, and serves on the editorial boards of multiple specialty journals. Dr. McCullough has made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, U.S. Food and Drug Administration (FDA), European Medicines Agency, and the U.S. Congressional Oversight Panel.


    We are in the midst of a heart failure pandemic. There have been advances in medical and device therapy for patients with heart failure and reduced left ventricular ejection fraction.  In vitro diagnostic testing has been important in establishing prognosis as well as a guide to management.  Natriuretic Peptides are currently used in diagnosis, prognosis, screening, and response to treatment for patients with heart failure. Galectin-3 is another blood biomarker of heart failure. Its concentrations are prognostic for heart failure hospitalization and death.  Levels of natriuretic peptides and galectin-3 are complementary in clinical practice.

    After this webinar you will be able to;-

    • Describe the key challenges of Heart Failure
    • Discuss the differences between natriuretic peptides BNP and NT-proBNP for the diagnosis, stratification and management of Heart Failure
    • Understand the clinical utility and additive effect of Galectin-3 with natriuretic peptides for prognosis of Heart Failure

    Show Resources
    Show Resources
    Connect with us